Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on May 22, 2019, reporting events that occurred on May 16, 2019. The company is incorporated in Delaware and operates as an emerging growth company. The filing addresses significant changes in executive leadership and board composition.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- CEO Resignation: Kelly Huang resigned as President and Chief Executive Officer, effective May 20, 2019. He is expected to continue serving as a consultant to the company.
- Executive Promotion: William Plovanic was promoted to President, effective May 20, 2019, while retaining his title as Chief Financial Officer.
- Board Appointment: William Plovanic was appointed as a Class I director on the Board of Directors.
- Leadership Continuity: Andy Rasdal continues to serve as Executive Chairman.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, market outlook, or specific risk factors related to the leadership changes. It references the company's 2018 Annual Report (Form 10-K) for background information on Mr. Plovanic's compensation and related party transactions. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the terms of Kelly Huang's consulting agreement following his resignation.
- Review William Plovanic's background and compensation details in the referenced 2018 Form 10-K Amendment No. 1.
- Confirm the interim leadership structure with Andy Rasdal as Executive Chairman and William Plovanic as President/CEO.
- Check for any subsequent filings regarding the appointment of a permanent CEO if Mr. Plovanic's role is intended as interim.